| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss | -35,902 | 15,886 | -17,710 | -24,183 |
| Foreign currency translation adjustment | -10 | 12 | 32 | -15 |
| Total comprehensive loss | -35,912 | 15,898 | -17,678 | -24,198 |
| Basic (in dollars per share) | -1.38 | 0.51 | -0.68 | -1.13 |
| Basic (in shares) | 26,002,892 | 25,980,262 | 25,902,650 | 21,471,408 |
| Diluted (in dollars per share) | -1.38 | 0.5 | -0.68 | -1.13 |
| Diluted (in shares) | 26,002,892 | 26,447,251 | 25,902,650 | 21,471,408 |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)